Indications for Implantable Cardioverter-Defibrillators Based on Evidence and Judgment

Journal of the American College of Cardiology

Volumn 54, Issue 9, 2009, Pages 747-763

  Myerburg, Robert J ^a   Reddy, Vivek ^a   Castellanos, Agustin ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

implantable cardioverter defibrillators; indications; review

Indexed keywords

ANTIARRHYTHMIC AGENT; PROCAINAMIDE;

ATHEROGENESIS; CARDIOMYOPATHY; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEFIBRILLATOR; EVIDENCE BASED PRACTICE; HEALTH CARE DELIVERY; HEART ARREST; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MYOCARDITIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SARCOIDOSIS; SECONDARY PREVENTION;

CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DEFIBRILLATORS, IMPLANTABLE; DELIVERY OF HEALTH CARE; HUMANS; MYOCARDIAL INFARCTION; PRIMARY PREVENTION; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS;

EID: 68749094230     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.03.078     Document Type: Review

References (112)

1. Mirowski M., Reid P.R., Mower M.M., et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 303 (1980) 322-344
2. Mirowski M., Mower M.M., Staewen W.S., Tabatznik B., and Mendeloff A.I. Standby automatic defibrillator. An approach to prevention of sudden coronary death. Arch Intern Med 126 (1970) 158-161
3. Mirowski M., Mower M.M., and Mendeloff A.I. Implanted standby defibrillators. Circulation 47 (1973) 1135-1136
4. Lown B., and Axelrod P. Implanted standby defibrillators. Circulation 46 (1972) 637-639
5. Langer A., Heilman M.S., Mower M.M., and Mirowski M. Considerations in the development of the automatic implantable defibrillator. Med Instrum 10 (1976) 163-167
6. Mirowski M., Mower M.M., Langer A., Heilman M.S., and Schreibman J. A chronically implanted system for automatic defibrillation in active conscious dogs. Experimental model for treatment of sudden death from ventricular fibrillation. Circulation 58 (1978) 90-94
7. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321 (1989) 406-412
8. Echt D.S., Liebson P.R., Mitchell L.B., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788
9. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335 (1996) 1933-1940
10. Bigger Jr. J.T., and Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 337 (1997) 1569-1575
11. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337 (1997) 1576-1580
12. Buxton A.E., Lee K.L., Fisher J.D., Josephson M.E., Prystowsky E.N., Hafley G., and Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341 (1999) 1882-1890
13. Connolly S.J., Gent M., Roberts R.S., et al., CIDS Investigators. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101 (2000) 1297-1302
14. Kuck K.H., Cappato R., Siebels J., and Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 102 (2000) 748-754
15. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
16. Hohnloser S.H., Kuck K.H., Dorian P., et al., DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 (2004) 2481-2488
17. Kadish A., Dyer A., Daubert J.P., et al., Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004) 2151-2158
18. Bardy G.H., Lee K.L., Mark D.B., et al., Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
19. Myerburg R.J., and Castellanos A. Emerging paradigms of the epidemiology and demographics of sudden cardiac arrest. Heart Rhythm 3 (2006) 235-239
20. Schaffer W.A., and Cobb L.A. Recurrent ventricular fibrillation and modes of death in survivors of out-of-hospital ventricular fibrillation. N Engl J Med 293 (1975) 259-262
21. Cobbe S.M., Dalziel K., Ford I., and Marsden A.K. Survival of 1476 patients initially resuscitated from out of hospital cardiac arrest. Br Med J 312 (1996) 1633-1637
22. Zipes D.P., Camm A.J., Borggrefe M., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 48 (2006) 1064-1108
23. Wyse D.G., Friedman P.L., Brodsky M.A., et al., AVID Investigators. Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. J Am Coll Cardiol 38 (2001) 1718-1724
24. Connolly S.J., Hallstrom A.P., Cappato R., et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics Vs. Implantable Defibrillator study, Cardiac Arrest Study Hamburg, Canadian Implantable Defibrillator Study. Eur Heart J 21 (2000) 2071-2078
25. Domanski M.J., Sakseena S., Epstein A.E., et al., AVID Investigators. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. J Am Coll Cardiol 34 (1999) 1090-1095
26. Feinstein A.R. Meta-analysis: statistical alchemy for the 21st century. J Clin Epidemiol 48 (1995) 71-79
27. Buxton A.E., Marchlinski F.E., Flores B.T., Miller J.M., Doherty J.U., and Josephson M.E. Nonsustained ventricular tachycardia in patients with coronary artery disease: role of electrophysiologic study. Circulation 75 (1987) 1178-1185
28. Wilber D.J., Olshansky B., Moran J.F., and Scanlon P.J. Electrophysiological testing and nonsustained ventricular tachycardia: use and limitation in patients with coronary artery disease and impaired ventricular function. Circulation 82 (1990) 350-358
29. Bourke J.P., Richards D.A.B., Ross D.L., Wallace E.M., McGuire M.A., and Uther J.B. Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol 18 (1991) 780-788
30. Julian D.G., Camm A.J., Frangin G., et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 349 (1997) 667-674
31. Cairns J.A., Connolly S.J., Roberts R., and Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 349 (1997) 675-682
32. Mukharji J., Rude R.E., Poole W.K., Gustafson N., et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol 54 (1984) 31-36
33. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 309 (1983) 331-336
34. Ross A.M., Coyne K.S., Moreyra E., et al. Extended mortality benefit of early postinfarction reperfusion. Circulation 97 (1998) 1549-1556
35. Solomon S.D., Zelenkofske S., McMurray J.J.V., et al., Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352 (2005) 2581-2588
36. Epstein A.E., DiMarco J.P., Ellenbogen K.A., et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 51 (2008) 2085-2105
37. Oechslin E.N., Harrison D.A., Connelly M.S., et al. Mode of death in adults with congenital heart disease. Am J Cardiol 86 (2000) 1111-1116
38. Myerburg R.J., and Castellanos A. Cardiac arrest and sudden cardiac death. In: Libby P., Bonow R.O., Mann D.L., and Zipes D.P. (Eds). Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8th edition (2008), Elsevier, Philadelphia, PA 933-974
39. Diaz F.J., Loewe C., and Jackson A. Death caused by myocarditis in Wayne County, Michigan: a 9-year retrospective study. Am J Forensic Med Pathol 27 (2006) 300-303
40. Winters S.L., Cohen M., Greenberg S., et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol 18 (1991) 937-943
41. Frank S., and Braunwald E. Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history. Circulation 37 (1968) 759-788
42. Maron B.J., Shen W.K., Link M.S., et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342 (2000) 365-373
43. Ellenbogen K.A., Levine J.H., Berger R.D., et al., Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?. Circulation 113 (2006) 776-782
44. Maron B.J., Spirito P., Shen W.K., et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. (erratum in: JAMA 2007;298:1516). JAMA 298 (2007) 405-412
45. Maron M.S., Olivotto I., Betocchi S., et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348 (2003) 295-303
46. Calkins H., and Marcus F. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: an update. Curr Cardiol Rep 10 (2008) 367-375
47. Buja G., Estes III N.A., Wichter T., Corrado D., Marcus F., and Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: risk stratification and therapy. Prog Cardiovasc Dis 50 (2008) 282-293
48. Wichter T., Paul M., Wollmann C., et al. Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation 109 (2004) 1503-1508
49. Liu N., Ruan Y., and Priori S.G. Catecholaminergic polymorphic ventricular tachycardia. Prog Cardiovasc Dis 51 (2008) 23-30
50. Gaita F., Giustetto C., Bianchi F., et al. Short QT syndrome. A familial cause of sudden death. Circulation 108 (2003) 965-970
51. Haissaguerre M., Derval N., Sacher F., et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med 358 (2008) 2016-2023
52. Moss A.J., and Schwartz P.J. 25th anniversary of the International Long-QT Syndrome Registry: an ongoing quest to uncover the secrets of long-QT syndrome. Circulation 111 (2005) 1199-1201
53. Zareba W., Moss A.J., Daubert J.P., Hall W., Robinson J., and Andrews M. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 14 (2003) 337-341
54. Goldenberg I., Moss A.J., Peterson D.R., et al. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation 117 (2008) 2184-2191
55. Kaufman E., McNitt S., Moss A.J., et al. Risk of death in the long QT syndrome when a sibling has died. Heart Rhythm 5 (2008) 831-836
56. Myerburg R.J., and Castellanos A. Sudden cardiac death. In: Zipes D.P., and Jalife J. (Eds). Cardiac Electrophysiology: From Cell to Bedside. 5th edition (2009), Elsevier, New York, NY In press
57. Brugada P., and Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 20 (1992) 1391-1396
58. Nademanee K., Veerakul G., Nimmannit S., et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 96 (1997) 2595-2600
59. Alings M., and Wilde A. "Brugada" syndrome: clinical data and suggested pathophysiological mechanism. Circulation 99 (1999) 666-673
60. Priori S.G., Napolitano C., Gasparini M., et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 105 (2002) 1342-1347
61. Antzelevitch C., Brugada P., Borggrefe M., et al. Brugada syndrome. Report of the Second Consensus Conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 111 (2005) 659-670
62. Myerburg R.J., and Castellanos A. Early repolarization and sudden cardiac arrest: theme or variation on a theme?. Nat Clin Pract Cardiovasc Med (2008 Oct 7) [Epub ahead of print]
63. Myerburg R.J. Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med 359 (2008) 2245-2253
64. Myerburg R.J., and Castellanos A. Clinical research designs and implantable defibrillator indications: spend in the beginning or pay at the end. J Am Coll Cardiol 47 (2006) 108-111
65. Phurrough S.E., Salive M.E., Baldwin J.F., Chin J., and Centers for Medicare and Medicaid Services. Decision memorandum for implantable defibrillators (CAG-00157R3), January 27, 2005. http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=148 Accessed November 20, 2008
66. McClellan M.B., and Tunis S.R. Medicare coverage of ICDs. N Engl J Med 352 (2005) 222-224
67. Nanthakumar K., Epstein A.E., Kay G.N., Plumb V.J., and Lee D.S. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 44 (2004) 2166-2172
68. Buxton A.E. Sudden death after myocardial infarction who needs prophylaxis, and when?. N Engl J Med 352 (2005) 2638-2640
69. Passman R., and Kadish A. Sudden death prevention with implantable devices. Circulation 116 (2007) 561-571
70. Ezekowitz J.A., Rowe B.H., Dryden D.M., et al. Implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med 147 (2007) 251-262
71. Goldberger J.J., Cain M.E., Hohnloser S.H., et al., American Heart Association; American College of Cardiology Foundation; Heart Rhythm Society. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. J Am Coll Cardiol 52 (2008) 1179-1199
72. Tung R., Zimetbaum P., and Josephson M.E. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 52 (2008) 1111-1121
73. Stein K.M. Noninvasive risk stratification for sudden death: signal-averaged electrocardiography, nonsustained ventricular tachycardia, heart rate variability, baroreflex sensitivity, and QRS duration. Prog Cardiovasc Dis 51 (2008) 106-117
74. Moss A.J., Fadl Y., Zareba W., Cannom D.S., Hall W.J., and Defibrillator Implantation Trial Research Group. Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. Am J Cardiol 88 (2001) 516-520
75. Hill A.B. The environment and disease. Association or causation?. Proc Royal Soc Med 58 (1965) 295-300
76. Huikuri H.V., Tapanainen J.M., Lindgren K., et al. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. J Am Coll Cardiol 42 (2003) 652-658
77. Greenberg H., Case R.B., Moss A.J., Brown M.W., Carroll E.R., and Andrews M.L. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 43 (2004) 1459-1465
78. Goldenberg I., Moss A.J., Hall W.J., et al., Multicenter Automatic Defibrillator Implantation Trial (MADIT) II Investigators. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 113 (2006) 2810-2817
79. Goldenberg I., Vyas A.K., Hall W.J., et al., MADIT-II Investigators. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 51 (2008) 288-296
80. Poole J.E., Johnson G.W., Hellkamp A.S., et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 359 (2008) 1009-1017
81. Buxton A.E., Sweeney M.O., Wathen M.S., et al., PainFREE Rx II Investigators. QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverter defibrillators. J Am Coll Cardiol 46 (2005) 310-316
82. Singh J.P., Hall W.J., McNitt S., et al. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J Am Coll Cardiol 46 (2005) 1712-1720
83. Wang N.C., Maggioni A.P., Konstam M.A., et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA 299 (2008) 2656-2666
84. Wilber D.J., Zareba W., Hall W.J., et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 109 (2004) 1082-1084
85. Myerburg R.J., Kessler K.M., and Castellanos A. Sudden cardiac death: structure, function, and time-dependence of risk. Circulation 85 Suppl 1 (1992) 2-10
86. Myerburg R.J. Sudden cardiac death: exploring the limits of our knowledge. J Cardiovasc Electrophysiol 12 (2001) 369-381
87. Epstein A.E. Benefits of the implantable cardioverter-defibrillator. J Am Coll Cardiol 52 (2008) 1122-1127
88. Buxton A.E., Lee K.L., Hafley G.E., et al., MUSTT Investigators. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol 50 (2007) 1150-1157
89. Solomon S.D., Glynn R.J., Greaves S., et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med 134 (2001) 451-458
90. Halkin A., Stone G.W., Dixon S.R., et al. Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. Am J Cardiol 96 (2005) 325-331
91. Buxton A.E. Not everyone with an ejection fraction <30% should receive an implantable cardioverter-defibrillator. Circulation 111 (2005) 2537-2542
92. Moss A.J. Everyone with an ejection fraction less than or equal to 30% should receive an implantable cardioverter-defibrillator. Circulation 111 (2005) 2542-2548
93. Bloomfield D.M., Steinman R.C., Namerow P.B., et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. Circulation 110 (2004) 1885-1889
94. Yan A.T., Shayne A.J., Brown K.A., et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation 114 (2006) 32-39
95. Schmidt A., Azevedo C.F., Cheng A., et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation 115 (2007) 2006-2014
96. Haigney M.C., Zareba W., Gentlesk P.J., et al. QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol 44 (2004) 1481-1487
97. Bauer A., Kantelhardt J.W., Barthel P., et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet 367 (2006) 1674-1681
98. Barthel P., Schneider R., Bauer A., et al. Risk stratification after acute myocardial infarction by heart rate turbulence. Circulation 108 (2003) 1221-1226
99. Makikallio T.H., Barthel P., Schneider R., et al. Prediction of sudden cardiac death after acute myocardial infarction: role of Holter monitoring in the modern treatment era. Eur Heart J 26 (2005) 762-769
100. Jouven X., Desnos M., Guerot C., and Ducimetière P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 99 (1999) 1978-1983
101. Dekker L.R., Bezzina C.R., Henriques J.P., et al. Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation 114 (2006) 1140-1145
102. Kaikkonen K.S., Kortelainen M.L., Linna E., and Huikuri H.V. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation 114 (2006) 1462-1467
103. Myerburg R.J. Scientific gaps in the prediction and prevention of sudden cardiac death. J Cardiovasc Electrophysiol 13 (2002) 709-723
104. Sanders G.D., Hlatky M.A., and Owens D.K. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353 (2005) 1471-1480
105. Mark D.B., Nelson C.L., Anstrom K.J., et al., SCD-HeFT Investigators. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 114 (2006) 135-142
106. Zwanziger J., Hall W.J., Dick A.W., et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 (2006) 2310-2318
107. Buxton M., Caine N., Chase D., et al., Health Economics Research Group. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modeling of cost-effectiveness and cost-utility for these groups in a UK context. Health Technol Assess 10 (2006) 1-164
108. Reynolds M.R., Cohen D.J., Kugelmass A.D., et al. The frequency and incremental cost of major complications among Medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol 47 (2006) 2493-2497
109. Groeneveld P.W., Farmer S.A., Suh J.J., Matta M.A., and Yang F. Outcomes and costs of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death among the elderly. Heart Rhythm 5 (2008) 646-653
110. Moss A.J., Greenberg H., Case R.B., et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 110 (2004) 3760-3765
111. Thurow L.C. The implosion of medicine, ethics, and economics. N Engl J Med 311 (1984) 1569-1572
112. Fuchs V.R. The "rationing" of medical care. N Engl J Med 311 (1984) 1572-1573